REGULATORY
Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
The Ministry of Health, Labor and Welfare (MHLW) on March 7 issued a new Q&A guide for its Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs, which was revised in March 2024. The revised guidelines specify that…
To read the full story
Related Article
- Japan’s Revised Drug Distribution Guidelines Take Effect
March 4, 2024
REGULATORY
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
- MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
March 18, 2026
- MHLW Orders Label Revisions for Antiepileptics and Other Drugs
March 18, 2026
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





